Alpha 2.0
Login Register
» Authors » Klaus Mantwill

Klaus Mantwill

Explore the profile of Klaus Mantwill including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 256
Followers 0
Related Specialties
Oncology
Biochemistry
Pharmacology
Top 10 Co-Authors
Per Sonne Holm
Roman Nawroth
Hermann Lage
Bernd Gansbacher
Per S Holm
Maximilian Ehrenfeld
Karsten Jurchott
Alexandra Bernshausen
Gabriel Glockzin
Hans-Dieter Royer
Published In
J Virol
Cancer Res
Hum Gene Ther
Int J Mol Sci
J Biol Chem
Affiliations
Soon will be listed here.
Recent Articles
11.
YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma
Holzmuller R, Mantwill K, Haczek C, Rognoni E, Anton M, Kasajima A, et al.
Int J Cancer . 2011 Jun; 129(5):1265-76. PMID: 21710499
The human Y-box binding protein 1 (YB-1) is known to be a promising target for cancer therapy. We have demonstrated that YB-1 plays an important role in the adenoviral life...
12.
Impact of radiation therapy on the oncolytic adenovirus dl520: implications on the treatment of glioblastoma
Bieler A, Mantwill K, Holzmuller R, Jurchott K, Kaszubiak A, Stark S, et al.
Radiother Oncol . 2007 Oct; 86(3):419-27. PMID: 17967494
Background And Purpose: Viral oncolytic therapy is emerging as a new form of anticancer therapy and has shown promising preclinical results, especially in combination with radio- and chemotherapy. We recently...
13.
Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents
Mantwill K, Kohler-Vargas N, Bernshausen A, Bieler A, Lage H, Kaszubiak A, et al.
Cancer Res . 2006 Jul; 66(14):7195-202. PMID: 16849566
Bearing in mind the limited success of available treatment modalities for the therapy of multidrug-resistant tumor cells, alternative and complementary strategies need to be developed. It is known that the...
14.
Characterization of the recombinant adenovirus vector AdYB-1: implications for oncolytic vector development
Glockzin G, Mantwill K, Jurchott K, Bernshausen A, Ladhoff A, Royer H, et al.
J Virol . 2006 Mar; 80(8):3904-11. PMID: 16571807
Conditionally replicating adenoviruses are a promising new modality for the treatment of cancer. However, early clinical trials demonstrate that the efficacy of current vectors is limited. Interestingly, DNA replication and...
15.
Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520
Bieler A, Mantwill K, Dravits T, Bernshausen A, Glockzin G, Kohler-Vargas N, et al.
Hum Gene Ther . 2006 Jan; 17(1):55-70. PMID: 16409125
Resistance to radiation and chemotherapy remains an obstacle to the treatment of brain tumors. We have demonstrated that the replication-deficient adenovirus d1520, which lacks the E1A 13S protein, replicates efficiently...
16.
Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: impact for cancer gene therapy
Holm P, Lage H, Bergmann S, Jurchott K, Glockzin G, Bernshausen A, et al.
Cancer Res . 2004 Jan; 64(1):322-8. PMID: 14729641
Resistance to chemotherapy is responsible for a failure of current treatment regimens in cancer patients. We have reported previously that the Y-box protein YB-1 regulates expression of the P-glycoprotein gene...
17.
YB-1 relocates to the nucleus in adenovirus-infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter
Holm P, Bergmann S, Jurchott K, Lage H, Brand K, Ladhoff A, et al.
J Biol Chem . 2002 Jan; 277(12):10427-34. PMID: 11788582
The adenovirus early proteins E1A and E1B-55kDa are key regulators of viral DNA replication, and it was thought that targeting of p53 by E1B-55kDa is essential for this process. Here...